Gout and risk of non-alcoholic fatty liver disease

References

• Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002;123:1705–25.
   PubMedGoogle Scholar
• Rector RS, Thyfault JP, Wei Y, Ibdah JA. Non-alcoholic fatty liver disease and the metabolic syndrome: an update. World J Gastroenterol 2008;14:185–92.
   PubMed Web of Science ®Google Scholar
• Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–23.
   PubMed Web of Science ®Google Scholar
• Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–19.
   PubMed Web of Science ®Google Scholar
• Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57:109–15.
   PubMed Web of Science ®Google Scholar
• Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008;20:187–91.
   PubMed Web of Science ®Google Scholar
• Lin WY, Liu CS, Li TC, Lin T, Chen W, Chen CC, In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study (Taichung Community Health Study). Ann Rheum Dis 2008;67:432–3.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Saldalamacchia G, Conca P, Arena A. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol 2007;22:293–303.
   PubMed Web of Science ®Google Scholar
• Shifflet A, Wu GY. Non-alcoholic steatohepatitis: an overview. J Formos Med Assoc 2009;108:4–12.
   PubMedGoogle Scholar
• Perez-Ruiz F, Schlesinger N. Management of gout. Scand J Rheumatol 2008;37:81–9.
   PubMed Web of Science ®Google Scholar
• Jansen TL, Reinders MK, van Roon EN, Brouwers JR. Benzbromarone withdrawn from the European market: another case of ‘absence of evidence is evidence of absence’? Clin Exp Rheumatol 2004;22:651.
   PubMed Web of Science ®Google Scholar
• Tam S, Carroll W. Allopurinol hepatotoxicity. Am J Med 1989;86:357–8.
   PubMedGoogle Scholar
• Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182–6.
   PubMed Web of Science ®Google Scholar
• Bureau of Health Promotion. The criteria of metabolic syndrome. Taiwan: Bureau of Health Promotion, Department of Health, 2003.
   Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. J Am Med Assoc 2003;289:2560–72.
   PubMed Web of Science ®Google Scholar
• Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937–44.
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.
   Google Scholar
• Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708–15.
   PubMed Web of Science ®Google Scholar
• Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol 2002;17(Suppl 3):S377–84.
   PubMedGoogle Scholar
• Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007;11:75–104, ix.
   PubMedGoogle Scholar
• Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, Dominguez-Diez A, Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 2001;34:1158–63.
   PubMed Web of Science ®Google Scholar
• Li XL, Man K, Ng KT, Lee TK, Lo CM, Fan ST. Insulin in UW solution exacerbates hepatic ischemia/reperfusion injury by energy depletion through the IRS-2/SREBP-1c pathway. Liver Transpl 2004;10:1173–82.
   PubMedGoogle Scholar
• Paradis V, Perlemuter G, Bonvoust F, Dargere D, Parfait B, Vidaud M, High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001;34:738–44.
   PubMed Web of Science ®Google Scholar
• Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond) 1997;92:51–8.
   PubMedGoogle Scholar
• Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002;417:447–52.
   PubMed Web of Science ®Google Scholar
• Lopez-Suarez A, Elvira-Gonzalez J, Bascunana-Quirell A, Rosal-Obrador J, Michan-Dona A, Escribano-Serrano J, Serum urate levels and urinary uric acid excretion in subjects with metabolic syndrome (in Spanish). Med Clin (Barc) 2006;126:321–4.
   PubMed Web of Science ®Google Scholar
• Strazzullo P, Barbato A, Galletti F, Barba G, Siani A, Iacone R, Abnormalities of renal sodium handling in the metabolic syndrome. Results of the Olivetti Heart Study. J Hypertens 2006;24:1633–9.
   PubMed Web of Science ®Google Scholar
• Puig JG, Martinez MA, Mora M, Fraile JM, Montoya F, Torres RJ. Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study. Nucleosides Nucleotides Nucleic Acids 2008;27:620–3.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009;50:1029–34.
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009;21:504–11.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688–96.
   PubMed Web of Science ®Google Scholar
• Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med 2008;168:1104–10.
   PubMed Web of Science ®Google Scholar
• Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116:894–900.
   PubMed Web of Science ®Google Scholar
• Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297–307.
   PubMed Web of Science ®Google Scholar
• Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010;49:141–6.
   PubMed Web of Science ®Google Scholar